Navigation Links
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Date:1/14/2008

sion- dependent patients on Vidaza achieved transfusion independence compared to 11 percent of transfusion-dependent patients on CCR, and for patients on Vidaza, the median time to transformation to AML during the treatment period was 26 months, compared to 12 months for patients on CCR therapy.

Treatment with Vidaza was well tolerated, demonstrating a safety profile consistent with previous experience.

Vidaza is the first of a new class of anti-cancer compounds known as demethylating agents, a subset of a category of drugs referred to as epigenetic therapies. Epigenetics refers to changes in the regulation of gene expression. DNA methylation and histone deacetylation are two of the more widely studied epigenetic mechanisms.

About Vidaza

In May 2004, the FDA approved Vidaza, the first in a new class of drugs called demethylation agents, for treatment of all five subtypes of Myelodysplastic Syndromes (MDS). These subtypes include: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of Vidaza required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of Vidaza cause the death of rapidly dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms. Non- proliferating cells are relatively insensitive to Vidaza. Vidaza was approved in the U.S. for IV administration in January 2007.
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
2. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
3. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
4. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
5. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MERIDIAN, Idaho , Jan. 23, 2015  Now available ... Patent No. 7,849,611) support that prevents ankle sprains by ... a brace, it fits securely around the outside of ... ankle mobility & comfort while still offering protection against ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... May 1, 2012 /PRNewswire-Asia-FirstCall/ -- ShangPharma Corporation (NYSE: ... leading China-based pharmaceutical and biotechnology research and development ... its annual report on Form 20-F for the ... States Securities and Exchange Commission (the "SEC"). The ...
... 2012 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... live webcast on Tuesday, May 8, 2012 at 4:30 p.m. ... a business and financial update and review first quarter 2012 ... be accessed from the Investors section of the Jazz Pharmaceuticals ...
Cached Medicine Technology:ShangPharma Corporation Files 2011 Annual Report on Form 20-F 2
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... , Shaking hands with a robotic arm could be a ... arms again. Researchers writing in BioMed Central,s open access ... of the ,Braccio di Ferro, (Iron arm) robot in 10 ... worked with a team of researchers from the Italian Institute ...
... (March 15, 2010) New research findings published in the ... of Surgeons indicate that some breast cancers continue to ... through mammographic screening. Patients who presented with palpable tumors ... examination had larger tumors and were at a more ...
... ... symptoms.* , ... Clemente, CA (Vocus) March 15, 2010 -- Metagenics, Inc. announced today that ... to address the needs of menopausal women. The key active ingredient in Estrovera is ...
... National Alliance of Wound Care® (NAWC®), in cooperation ... Patient Safety and the New Jersey Department of Health and ... to expand the number of wound care certified professionals through ... This new initiative was borne of the idea of making ...
... March 15 (OTC Bulletin Board: WNDM) Wound ... products, announced today that its subsidiary Wound Care Innovations ... Conference in Los Angeles March 18-20 ... researchers, scientists, and limb salvage experts from all 50 ...
... Taking antidepressant plus naltrexone improves odds of not drinking, ... Combined treatment with the antidepressant Zoloft (sertraline) and the ... both major depression and alcohol dependence will be able ... study of 170 patients found that 54 percent of ...
Cached Medicine News:Health News:Palpable breast cancers are more common in women not undergoing annual mammography 2Health News:Palpable breast cancers are more common in women not undergoing annual mammography 3Health News:Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms* 2Health News:Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms* 3Health News:Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms* 4Health News:New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals 2Health News:New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals 3Health News:New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals 4Health News:New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals 5Health News:Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference 2Health News:Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference 3Health News:Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference 4Health News:Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference 5
... Anatomic Knee system was designed to ... all articulating surfaces, to minimize contact ... achieve a well balanced knee with ... The MJS Knee system allows maximum ...
... of digital mobile imaging just got ... software and instrumentation. Now using,your C-arm ... Easily Add Visualization and Navigation ... Accelerate Intraoperative Decision Making, Provide ...
... GE's surgical navigation for ... system to integrate C-arm ... technology. It features automatic ... image to the patient's ...
... on over 20 years of CT engineering ... is at the forefront of the revolution ... acquire volumetric data at high speed with ... based on extensive clinical experience and close ...
Medicine Products: